Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors MA Gouda, V Subbiah American Society of Clinical Oncology Educational Book 43, e404770, 2023 | 33 | 2023 |
Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy MA Gouda, V Subbiah ESMO open 8 (2), 100788, 2023 | 33 | 2023 |
Tumor-agnostic precision medicine from the AACR GENIE database: clinical implications MA Gouda, BE Nelson, L Buschhorn, A Wahida, V Subbiah Clinical Cancer Research 29 (15), 2753-2760, 2023 | 29 | 2023 |
Medical Undergraduates' Contributions to Publication Output of World's Top Universities in 2013 MA Gouda, HS Zidan, AA Marey, MG Gameal, RG Elmahrook, A Saleh, ... QJM, 2016 | 25 | 2016 |
Family medicine in Egypt from medical students' perspective: a nationwide survey MM AlKot, MA Gouda, MT KhalafAllah, MS Zahran, MM Kallaf, AM Zayed Teaching and learning in medicine 27 (3), 264-273, 2015 | 22 | 2015 |
Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers MA Gouda, HJ Huang, SA Piha-Paul, SG Call, DD Karp, S Fu, A Naing, ... JCO Precision Oncology 6, e2100512, 2022 | 19 | 2022 |
Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH-Mutated Cholangiocarcinoma Treated With Isocitrate … M Lapin, HJ Huang, S Chagani, M Javle, RT Shroff, S Pant, MA Gouda, ... JCO Precision Oncology 6, e2100197, 2022 | 15 | 2022 |
Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma MA Gouda, J Polivka, HJ Huang, I Treskova, K Pivovarcikova, T Fikrle, ... ESMO Open 7 (1), 100357, 2022 | 15 | 2022 |
N-of-1 Trials in Cancer Drug Development MA Gouda, L Buschhorn, A Schneeweiss, A Wahida, V Subbiah Cancer Discovery 13 (6), 1301-1309, 2023 | 13 | 2023 |
Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST) MA Gouda, F Janku, A Wahida, L Buschhorn, A Schneeweiss, NA Karim, ... Annals of Oncology, 2023 | 11 | 2023 |
Student research in arab world: what is the current state? OA Aboshady, MA Gouda Saudi medical journal 37 (6), 707, 2016 | 11 | 2016 |
ALK fusions in the pan-cancer setting: another tumor-agnostic target? A Shreenivas, F Janku, MA Gouda, HZ Chen, B George, S Kato, ... npj Precision Oncology 7 (1), 101, 2023 | 10 | 2023 |
Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer FM Johnson, F Janku, MA Gouda, HT Tran, JD Kawedia, D Schmitz, ... The Oncologist 27 (12), 1004-e926, 2022 | 10 | 2022 |
Ultrasensitive detection of BRAF V600E mutations in circulating tumor DNA of patients with metastatic thyroid cancer MA Gouda, E Ong, HJ Huang, LW McPhaul, S Yoon, F Janku, ... Endocrine 76 (2), 491-494, 2022 | 9 | 2022 |
Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers MA Gouda, V Subbiah Therapeutic Advances in Medical Oncology 15, 17588359231177015, 2023 | 8 | 2023 |
Pros and cons of student journals OA Aboshady, MA Gouda Perspectives on Medical Education, 1-2, 2016 | 5 | 2016 |
Pearls and pitfalls of ChatGPT in medical oncology J Blum, AK Menta, X Zhao, VB Yang, MA Gouda, V Subbiah Trends in Cancer, 2023 | 4 | 2023 |
Precision oncology for biliary tract tumors: it’s written in blood! MA Gouda, V Subbiah Annals of Oncology 33 (12), 1209-1211, 2022 | 4 | 2022 |
529MO Activity, safety and circulating tumour DNA (ctDNA) dynamics of paradox breaker BRAF inhibitor PLX8394 in patients with advanced cancer MA Gouda, EJ Sherman, GW Gilcrease, UN Vaishampayan, A Parikh, ... Annals of Oncology 31, S465, 2020 | 3 | 2020 |
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer V Subbiah, MA Gouda, JB Iorgulescu, R Dadu, K Patel, S Sherman, ... NPJ Precision Oncology 8 (1), 62, 2024 | 2 | 2024 |